Curran D, Patterson B, Carrico J, Salem A, La E, Lorenc S, Hicks K, Poston S, Carpenter C. Cost-effectiveness analysis of recombinant Zoster vaccine for the prevention of herpes Zoster in immunocompromised adults diagnosed with select cancers in the United States. Poster presented at the 2021 Lymphoma and Myeloma (L&M) Virtual Congress; October 2021. [abstract] Am J Hematol. 2021 Oct 15; 96(S1):S26. doi: 10.1002/ajh.26351
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Nabhan C, Zhou X, Day BM, Dawson K, Zelenetz AD, Friedberg JW, Cerhan JR, Link BK, Flowers CR. Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States. Am J Hematol. 2016 Aug;91(8):770-5. doi: 10.1002/ajh.24401
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Candrilli SD, O'Brien S, Ware RE, Balkrishnan R. Hydroxyurea adherence and associated outcomes in medicaid enrollees with sickle cell disease. Am J Hematol. 2011 Feb;86(3):273-7. doi: 10.1002/ajh.21968
Hegarty AC, Carsin AE, Comber H. Geographical analysis of cancer incidence in Ireland: comparison of two bayesian spatial models. Cancer Epidemiol. 2010 Aug;34(4):373-81. doi: 10.1016/j.canep.2010.04.019